Introduction {#Sec1}
============

Parathyroid glands (PTG) are nodular structures that are usually located along the posterior wall of the thyroid (Fig. [1](#Fig1){ref-type="fig"}). Their product, parathyroid hormone (PTH), plays an essential role in calcium homeostasis in the organism. Elevation of PTH can occur due to either overproduction by an adenomatous, hyperplastic, or rarely carcinomatous gland in primary hyperparathyroidism (PHPT) or due to hypocalcemia in secondary hyperparathyroidism (SHPT). Hypocalcemia may result from chronic kidney disease or malabsorption. The standard treatment for symptomatic patients with PHPT is surgical excision of transformed glands. If the underlying cause of hypocalcemia in patients with SHPT cannot be addressed or if patients are refractory to pharmacological therapy, a parathyroidectomy is the treatment of choice \[[@CR1]\].Fig. 1Anatomical relationships of parathyroid gland

The anatomy of PTG is highly variable in the population. Classically, four PTG are present, but previous research reported fewer and cases of up to 12 glands per patient \[[@CR2]\]. Parathyroid glands derive from endodermal tissue. Embryologically, the two superior glands descend from the fourth pharyngeal pouch and the two inferior glands from the third pharyngeal pouches \[[@CR3]\]. The superior glands are usually located on the upper pole of the thyroid, a short distance caudally from the intersection of the recurrent laryngeal nerve and inferior thyroid artery. Since the traveled distance of superior glands is shorter, their location is often more constant than the inferior glands \[[@CR3]\]. The latter descend along with the thymus, which also originates from the third pharyngeal pouch. Due to this fact, the glands can often be found along the descent pathway in the neck or mediastinum \[[@CR3]\]. Their most frequent location is the inferior pole of the thyroid, below the superior PTG.

Bilateral neck exploration is the classical approach to parathyroidectomy. Preoperative identification of PTG is of crucial importance, especially in patients with PHPT requiring excision of only one or few PTG and allows for a less invasive approach. Ultrasonography (USG), technetium-99m scintigraphy, or computed tomography are used to identify PTG preoperatively. Moreover, intraoperative PTH assay ensures that all PTG causing hyperparathyroidism are removed during surgery. Substantial research has been done to untangle the variable prevalence and location of PTG, but the results are inconsistent. Knowledge regarding the prevalence, location, and anatomy of PTG is essential for surgeons planning for and carrying out parathyroidectomies, as any unidentified PTG, either supernumerary or those in an ectopic location, can result in unsuccessful treatment and the need for reoperation. Moreover, the preservation of PTG is of utmost importance during thyroidectomies. Therefore, the aim of this study was to conduct a systematic analysis on the prevalence, location, and morphometric data of PTG in both healthy patients and those with hyperparathyroidism (HPT).

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

All major electronic databases, such as PubMed, Embase, ScienceDirect, SciELO, BIOSIS, and Web of Science were searched up to August 2018 for any studies reporting relevant data on the PTG. The following search terms were used: parathyroids OR parathyroid gland OR accessory parathyroid OR glandula parathyreoidea OR parathyroid bodies. The search was not limited by any date or language restrictions. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (*PRISMA*) guidelines were strictly followed throughout this study (Supplement [1](#MOESM1){ref-type="media"}).

Eligibility assessment {#Sec4}
----------------------

Two independent reviewers conducted eligibility assessment of any potential article. Any studies that were peer-reviewed and included data about the number of PTG per patient, location of PTG, or morphology of PTG were included into the meta-analysis. Studies that were conference abstracts, letters to editor, reviews, and studies with incomplete data were excluded. The articles published in languages other than English were translated by medical professionals, and their eligibility was assessed. Any dispute in the assessment of the eligibility was resolved by uniform consensus.

Data extraction {#Sec5}
---------------

Two independent reviewers extracted data from eligible articles. Data on the study type, number of PTG per patient, and location of PTG was extracted. Patients were subdivided into healthy and HPT groups. Patients who did not have any pathology of PTG were considered healthy. The PTG were classified into orthotopic, neck, or mediastinum based on location and later analyzed within each group. The superior PTG were considered orthotopic when located on the posterior aspect of the middle to upper pole of thyroid gland, while considered inferior PTG when located lateral to the inferior pole of the thyroid gland. Specific locations of ectopic glands in the neck and mediastinum were also noted when available.

Statistical analysis {#Sec6}
--------------------

Software MetaXL 5.4 by EpiGear International Pty Ltd. (Wilston, Queensland, Australia) was used to conduct statistical analysis. The pooled prevalence estimates (PPE) were calculated using a random effects model. The heterogeneity of the included studies was assessed with chi^2^ test and *I*^2^ statistic. Significant heterogeneity was determined if Cochrane Q *p* value \< 0.10 \[[@CR4]\]. The following intervals for *I*^2^ statistic were used: 0--40%---"might not be important," 30--60%---"might indicate moderate heterogeneity," 50--90%---"may indicate substantial heterogeneity," and 75--100%---"may represent considerable heterogeneity" \[[@CR4]\].

The data was divided into several subgroups. Whenever possible, the type of study, patient's health characteristic (healthy/HPT), and geographical location were analyzed separately. Moreover, sensitivity analysis by exclusion of studies with sample size smaller than 500 was performed to further investigate the source of heterogeneity. Confidence intervals were used to compare two groups, with any overlap as an indication of statistically insignificant difference \[[@CR5]\].

Results {#Sec7}
=======

Study identification {#Sec8}
--------------------

The flow of articles through the study is presented in Fig. [2](#Fig2){ref-type="fig"}. The initial search identified 1364 entries. After exclusion of duplicates and initial screening, 74 studies were analyzed by full text.Fig. 2Study identification flowchart

Finally, a total of 27 articles were included into the meta-analysis.

Characteristics of the included studies {#Sec9}
---------------------------------------

Twenty-seven studies \[[@CR2], [@CR6]--[@CR31]\] (*n* = 7106 patients, *n* = 23,519 PTG) analyzing the prevalence, location, or morphology of PTG were included. The dates of the included studies ranged from 1916 to 2016. Eleven studies originated from Europe, 6 from North America, 4 from South America, 5 from Asia, and 1 from Australia, and a total of 12 countries. Twelve studies analyzed healthy patients, and 10 studies analyzed patients with HPT, 2 with MEN1 and 2 with various thyroid diseases (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of included studiesStudy IDCountryType of studyPathologyNumber of patientsNumber of analyzed PTGAbboud 2008 \[[@CR4]\]LebanonIntraoperativeVarious thyroid disease5742219Akerstrom 1984 \[[@CR5]\]SwedenCadavericHealthy5032032Alveryd 1968 \[[@CR6]\]SwedenCadavericHealthy3521405Arnalsteen 2003 \[[@CR7]\]FranceIntraoperativeMEN179340Botelho 2004 \[[@CR8]\]BrazilCadavericHealthy1976Butterworth 1998 \[[@CR9]\]UKIntraoperativeSHPT60241de Andrade 2014 \[[@CR10]\]BrazilIntraoperativeSHPT166664Edis 1987 \[[@CR11]\]AustraliaIntraoperativeSHPT2073Ghandur 1986 \[[@CR12]\]USACadavericHealthy166502Gilmour 1938 \[[@CR13]\]UKCadavericHealthy4281713Gomes 2007 \[[@CR14]\]BrazilIntraoperativeSHPT35143Heinbach 1933 \[[@CR15]\]USACadavericHealthy2586Hellman 1998 \[[@CR16]\]SwedenIntraoperativeMEN150206Hibi 2002 \[[@CR17]\]JapanIntraoperativeSHPT822Hojaij 2011 \[[@CR18]\]BrazilCadavericHealthy56220Kawata 2008 \[[@CR19]\]JapanIntraoperativeSHPT44163Lappas 2012 \[[@CR20]\]GreeceCadavericHealthy9423796Milas 2003 \[[@CR21]\]USAIntraoperativePHPT8283250Nanka 2006\* \[[@CR22]\]Czech RepublicCadavericHealthy101280Numano 1998 \[[@CR23]\]JapanIntraoperativeSHPT5702377Okada 2016 \[[@CR24]\]JapanIntraoperativeSHPT131457Pacini 1983 \[[@CR25]\]ItalyIntraoperativePHPT and SHPT42163Périé 2005 \[[@CR26]\]FranceIntraoperativeSHPT2080Pool 1916 \[[@CR27]\]USACadavericHealthy2560Prazenica 2015 \[[@CR28]\]Czech RepublicIntraoperativeVarious thyroid disease7881937Pyrtek 1964 \[[@CR29]\]USACadavericHealthy100391Wang 1976 \[[@CR30]\]USACadavericHealthy160645*SHPT* secondary hyperparathyroidism, *PHPT* primary hyperparathyroidism\*Study included only in location analysis

Number of parathyroid glands per patient {#Sec10}
----------------------------------------

The overall analysis of 26 studies (*n* = 7005 patients) on the number of parathyroid glands showed that 81.4% (95% CI 65.4--85.8) have four PTG (Fig. [3](#Fig3){ref-type="fig"}). Sensitivity analysis showed no significant differences compared with the overall analysis with high heterogeneity persisting. The subgroup analysis of 14 intraoperative studies (*n* = 3399 patients) revealed that 82.2% (95% CI 59.1--92.7) of patients have four PTG (Table [2](#Tab2){ref-type="table"}). Similarly, 11 cadaveric studies (*n* = 2776 patients) showed that majority of patients have four PTG. Subgroup analysis of the healthy group based on geographical location revealed smaller prevalence of patients with four PTG both in North (62.5%; 95% CI 17.3--95.8) and South America (63.4%; 95% CI 32.1--93.7) than in Europe (90.9%; 95% CI 87.7--93.6); however, the differences were not significant. Overall, 4.9% and 6.3% of healthy and HPT patients, respectively, have five or more PTG (Table [2](#Tab2){ref-type="table"}). Table [3](#Tab3){ref-type="table"} presents data on the subgroup analysis of the number of PTG in studies reporting prevalence of up to 11 PTG.Fig. 3Forrest plot for overall pooled prevalence rate of patients with four parathyroid glandsTable 2Number of parathyroid glands per patientSubgroupNumber of studies (number of patients)PPE of patients with 0 PTG: % (95% CI)PPE of patients with 1 PTG: % (95% CI)PPE of patients with 2 PTG: % (95% CI)PPE of patients with 3 PTG: % (95% CI)PPE of patients with 4 PTG: % (95% CI)PPE of patients with 5 PTG or more: % (95% CI)*I*^2^: % (95% CI)Cochran's Q, *p* valueOverall26 (7005)0.5 (0--2.7)1.0 (0.0--4.0)2.6 (0.0--7.9)9.1 (2.8--16.6)81.4 (65.4--85.8)5.4 (0.8--11.8)98.9 (98.8--99.0)\< 0.001Sensitivity8 (5455)0.1 (0.0--4.6)0.3 (0.0--5.6)1.7 (0.0--9.8)7.1 (0.0--20.3)86.4 (61.3--96.8)4.4 (0.0--15.7)99.6 (99.6--99.7)\< 0.001Type of studyIntraoperative14 (3399)0.5 (0.0--5.2)1.0 (0.0--7.0)2.4 (0.0--10.3)7.3 (0.0--21.3)82.2 (59.1--92.7)6.6 (0.0--17.7)99.2 (99.0--99.3)\< 0.001Cadaveric11 (2776)0.5 (0.0--3.1)1.2 (0.0--4.6)4.1 (0.2--10.9)9.7 (2.8--18.2)79.6 (62.7--85.3)4.9 (0.4--11.9)97.5 (96.6--98.2)\< 0.001Geographical originEurope4 (2225)0.0 (0.0--0.4)0.0 (0.0--0.4)0.2 (0.0--0.8)3.9 (2.2--6.2)90.9 (87.7--93.6)4.9 (2.9--7.3)82.0 (53.5--93.0)0.001North America5 (476)1.2 (0.0--18.8)2.6 (0.0--23.8)12.5 (0.0--45.2)18.3 (0.0--54.2)62.5 (17.3--95.8)2.9 (0.0--24.7)98.5 (97.8--99.0)\< 0.001South America2 (75)0.7 (0.0--12.1)2.6 (0.0--18.6)7.6 (0.0--30.2)8.4 (0.0--31.7)63.4 (32.1--93.7)17.3 (0.0--46.7)83.5 (31.5--96.0)0.014Healthy patients11 (2776)0.5 (0.0--3.1)1.2 (0.0--4.6)4.1 (0.2--10.9)9.7 (2.8--18.2)79.6 (62.7--85.3)4.9 (0.4--11.9)97.5 (96.6--98.2)\< 0.001Hyperparathyroidism patients---overall10 (1910)0.4 (0.0--2.3)0.8 (0.0--3.4)1.4 (0.0--4.4)8.4 (3.1--15.4)82.7 (72.0--89.2)6.3 91.8--12.7)94.1 (91.1--96.1)\< 0.001Secondary hyperparathyroidism patients9 (1868)0.3 (0.0--2.4)0.7 (0.0--3.2)1.2 (0.0--4.4)8.8 (3.0--16.5)82.7 (70.8--89.4)6.4 (1.5--13.3)94.7 (91.9--96.6)\< 0.001MEN 12 (129)0.4 (0.0--5.7)0.4 (0.0--5.7)0.4 (0.0--5.7)0.4 (0.0--5.7)78.8 (59.2--95.2)19.6 (4.8--40.8)83.5 (31.6--96.0)0.014*PPE* pooled prevalence estimate, *PTG* parathyroid glandTable 3Number of parathyroid glands per patient (0--11)SubgroupNumber of studies (number of patients)PPE of patients with up to 4 PTG: % (95% CI)PPE of patients with 5 PTG: % (95% CI)PPE of patients with 6 PTG: % (95% CI)PPE of patients with 7 PTG: % (95% CI)PPE of patients with 8 PTG: % (95% CI)PPE of patients with 9 PTG: % (95% CI)PPE of patients with 10 PTG: % (95% CI)PPE of patients with 11 PTG: % (95% CI)*I*^2^: % (95% CI)Cochran's Q, *p* valueOverall^a^24 (6910)93.6 (91.9--97.1)4.5 (2.4--7.3)0.7 (0.0--1.8)0.3 (0.0--1.1)0.2 (0.0--1.0)0.2 (0.0--0.9)0.2 (0.0--0.9)0.2 (0.0--1.0)95.2 (93.8--96.2)\< 0.001Healthy patients6 (1191)91.9 (88.9--95.9)5.2 (2.6--8.7)1.7 (0.3--3.9)0.3 (0.0--1.2)0.3 (0.0--1.2)0.2 (0.0--1.0)0.2 (0.0--1.0)0.3 (0.0--1.2)72.3 (36.0--88.0)0.003Secondary hyperparathyroidism patients2 (1392)86.5 (81.5--90.8)12.1 (8.0--16.8)1.0 (0.0--2.9)0.4 (0.0--1.4)0.0 (0.0--0.5)0.0 (0.0--0.5)0.0 (0.0--0.5)0.0 (0.0--0.5)84.2 (35.0--96.2)0.012*PPE* pooled prevalence estimate, *PTG* parathyroid gland^a^Overall---includes healthy, MEN1, primary, and secondary hyperparathyroidism patients

Location of parathyroid glands {#Sec11}
------------------------------

Overall analysis of eight studies (*n* = 7529 PTG) showed that 15.9% of PTG are present in ectopic locations, with 11.6% (95% CI 5.1--19.1) in the neck and 4.3% (95% CI 0.7--9.9) in mediastinum (Table [4](#Tab4){ref-type="table"}). Five studies (*n* = 4324 PTG) of healthy patients and three studies (*n* = 1046 PTG) of HPT patients revealed that 94.7% and 82.5% of PTG are localized along the posterior wall of thyroid glands in or within close proximity to their orthotopic locations.Table 4Location of parathyroid glandsSubgroupNumber of studies (number of PTG)Orthotopic: % (95% CI)Neck: % (95% CI)Mediastinum: % (95% CI)*I*^2^: % (95% CI)Cochran's Q, *p* valueOverall8 (7529)84.1 (71.9--89.1)11.6 (5.1--19.1)4.3 (0.7--9.9)98.6 (98.1--99.0)\< 0.001Healthy5 (4324)94.7 (87.4--98.6)2.7 (0.0--7.9)2.7 (0.0--7.0)93.6 (88.0--96.6)\< 0.001Hyperparathyroidism patients3 (1046)82.5 (67.5--92.3)12.3 (3.4--24.5)5.2 (0.1--14.8)95.2 (89.2--97.8)\< 0.001

The subgroup analysis (nine studies, *n* = 435 PTG localized in the neck) showed that 31.4% (95% CI 0.6--63.8) of ectopic PTG in the neck are localized in retroesophageal/paraesophageal space, followed by 20.3% (95% CI 0.0--48.2) in the thyroid gland, 17.7% (95% CI 0.0--44.8) in the carotid sheath, 17.0% (95% CI 0.0--43.9) in the thyrothymic ligament, 5.1% (95% CI 0.0--25.1) in the tracheoesophageal groove, and 8.4% in other locations (thyroid cartilage, retropharyngeal space, adjacent to hyoid bone). The subgroup analysis of mediastinal PTG revealed that majority were located in the thymus.

Discussion {#Sec12}
==========

A careful resection of PTG in patients with HPT and preservation of these glands during thyroidectomies and other surgeries of the neck requires thorough knowledge on the anatomy and possible locations of PTGs. Instead of basing anatomical knowledge on epidemiological studies with small sample sizes, recent years have introduced meta-analysis as a powerful tool for elucidating the complex and variable human anatomy through an evidence-based approach \[[@CR32]\]. Therefore, this study aimed to systematically analyze available data on the prevalence and location of parathyroid glands utilizing meta-analysis.

The main findings of this study showed that majority of both healthy and HPT patients have four PTG. However, almost 19% of patients have fewer or more than four PTG. The prevalence of PTG is of particular interest for surgeons treating patients with SHPT. Those with SHPT due to advanced chronic kidney disease who are refractory to initial treatment with vitamin D analogs and calcimimetics are qualified for surgery \[[@CR1]\]. A recent meta-analysis has shown the superiority of surgery over pharmacological treatment in terms of all-cause and cardiovascular mortality \[[@CR1]\]. Currently, two approaches are advised---subtotal parathyroidectomy, which involves resection of most glands with partial in situ resection of the last one, and total parathyroidectomy with or without heterotopic autotransplantation of a small section of one gland into brachialis muscle. The study by Anderson et al. \[[@CR33]\] reported no evident advantage of either methods in terms of complication rates, readmission, and 30-day mortality. However, the success of both types of surgeries depends strongly on identification of all PTG. Our results showed that surgeons should expect that up to 1 in 15 patients will have five or more PTG. Moreover, one in six patients will have ectopically localized glands---with majority located in retroesophageal/paraesophageal space, thyroid, carotid sheath, thyrothymic ligament, and thymus. Subgroup analyses showed that most patients with supernumerary glands have five or six PTG and very rarely seven or more PTG. No differences were observed between healthy and HPT patients and between cadaveric and intraoperative studies.

The clinical picture of PHPT has evolved over time. The classic presentation of PHPT includes decreased bone density with accompanying fractures, renal manifestations such as nephrolithiasis, nephrocalcinosis, renal dysfunction, or neurocognitive symptoms, such as low energy, difficulty with concentration and memory, depression, and anxiety \[[@CR34]\]. However, due to widespread laboratory screening, most patients are diagnosed with PHPT in early stage when symptoms are rare or non-evident \[[@CR34]\]. While it is commonly agreed that symptomatic patients with PHPT should undergo surgery, the recommendations for operative treatment for asymptomatic patients have shifted. A study of natural history of PHPT by Rubin et al. \[[@CR35]\] showed that in more than third of the patients who did not undergo surgery, PHPT progressed over 15 years of follow-up and those patients eventually met criteria for surgical treatment. The current guidelines recommend parathyroidectomy for asymptomatic patients based on age, serum calcium level, bone density, and kidney function \[[@CR36]\]. However, it is important to note that parathyroidectomy should be considered for all PHPT patients, as surgery is the only cure for PHPT and is more cost-effective than pharmacological treatment or observation \[[@CR37]\].

Preoperative identification of enlarged and hyperfunctioning PTG is of crucial importance for successful minimally invasive procedures. While normal PTG are relatively difficult to visualize in USG, adenomatous, hyperplastic, or carcinomatous glands are more visible. The sensitivity of USG to identify enlarged PTG preoperatively reaches 70--100% \[[@CR38], [@CR39]\]. ^99m^Tc-sestamibi imaging of parathyroid glands can be used as an alternative or in conjunction with USG. This technique has a reported sensitivity of 54--100% \[[@CR40], [@CR41]\]. When compared, neither of the methods has been shown to be superior in detecting abnormal PTG when carried out by an experienced radiologist \[[@CR42]\]. A CT scan can provide additional information on the localization of PTG with a sensitivity ranging from 40 to 86% depending on the size of the gland \[[@CR43]\]. It can be useful in detecting missed PTG in sestamibi imaging, thus guiding focused exploration \[[@CR44]\]. However, all methods show diminished sensitivity in detecting PTG in rare ectopic locations, such as intrathyroid PTG. Our study showed that 20.3% of ectopic PTG in the neck are located in the thyroid gland. Surgeons should take caution for any intrathyroid PTG during parathyroidectomy, especially in the cases where bilateral neck exploration fails to identify a missing gland or intraoperative PTH assay does not show a decrease of PTH levels of more than 50%.

This meta-analysis was limited by high heterogeneity during the analyses. Despite conducting subgroup analyses to probe the source of heterogeneity, it persisted throughout the study. Additionally, there was a wide discrepancy in the method of reporting the number of glands per patient (especially with supernumerary glands and ectopic glands). The number of studies analyzing morphology of the PTG was also limited.

Conclusion {#Sec13}
==========

Most healthy and hyperparathyroidism patients have four parathyroid glands, but about 20% present with fewer or more glands. The number of ectopic glands reaches 16% and is located in the neck or mediastinum. Surgeons should be aware of the most frequent potential locations of ectopic PTG to assure successful surgery and treatment.
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